Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
50actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-15 | actual | When the study began enrolling |
| Primary completion | 2026-04-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-07 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Intervention
- Drug: Tafamidis — also filed as Vyndamax
Primary outcome
what the primary-completion date above is the date OFRate of neurologic disease progression
measured Baseline through at least 12 months of treatment
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed